Last edition
News about Biotechnology
IDT- Ansa Alliance Brings High-Complexity, Long-Length DNA Synthesis to Global Researchers
Integrated DNA Technologies (IDT), a Danaher company and a global genomics solutions provider, has entered into a strategic collaboration with Ansa Biotechnologies Inc to enhance its synthetic biology portfolio with advanced DNA synthesis capabilities.
Biotechnology | 17/01/2026 | By Darshana | 242
BD Secures FDA 510(k) Clearance for EnCor EnCompass Multi-Modality Breast Biopsy System
BD has received FDA 510(k) clearance for its EnCor EnCompass multi-modality breast biopsy system, designed to improve procedural efficiency, clinician flexibility and early detection and diagnosis of breast disease.
Biotechnology | 17/01/2026 | By News Bureau | 154
Risa Labs Raises USD 11.1M Series A to Scale AI OS for Oncology Care
The funding led by Cencora Ventures and Optum Ventures will accelerate nationwide deployment of Risa’s AI-driven platform to streamline oncology workflows, reduce delays and improve patient access to cancer therapies.
Biotechnology | 14/01/2026 | By News Bureau | 286
Dr Jitendra Singh Inaugurates SAMARTH Skill Centre, iDeA-NA Tech Incubator at DBT-CDFD, Hyderabad
While inaugurating the initiatives, Dr Jitendra Singh, Union Minister of State (Independent Charge), Science & Technology, Earth Sciences, and Minister of State, PMO, Department of Space and Department of Atomic Energy, highlighted India’s transition towards futuristic healthcare, early disease detection, affordability and personalised medicine.
Biotechnology | 12/01/2026 | By News Bureau | 157
Biocon Biologics to Showcase Keytruda and Two New Oncology Biosimilars at JPM 2026
Biocon Biologics, the biosimilars arm of Biocon Ltd, is set to introduce three new oncology biosimilars, including a biosimilar of pembrolizumab (Keytruda), at the J.P. Morgan Healthcare Conference 2026 in San Francisco.
Biotechnology | 07/01/2026 | By Darshana | 279
Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Worth Over USD 1 Billion
Eli Lilly & Company is in advanced discussions to acquire Ventyx Biosciences in a deal valued at more than USD 1 billion, according to reports citing people familiar with the matter. The acquisition talks have attracted strong investor interest, with Ventyx shares rising sharply following the news.
Biotechnology | 07/01/2026 | By Darshana | 186
WuXi Biologics, a global contract research, development and manufacturing organisation (CRDMO), has achieved ISO 20400 Sustainable Procurement certification, a globally recognised standard that embeds sustainability principles into procurement practices and promotes transparency, accountability and responsible supply chain management.
Biotechnology | 06/01/2026 | By Darshana | 149
Pandorum Partners with Nucelion Therapeutics to Manufacture Exosome-Based Ocular Therapy for APAC
Pandorum Technologies, a clinical-stage regenerative medicine company, has entered into a strategic manufacturing collaboration with Nucelion Therapeutics, the contract research, development and manufacturing organisation (CRDMO) arm of Bharat Biotech, to support the production of its exosome-based ocular disease therapy for the Asia-Pacific (APAC).
Biotechnology | 06/01/2026 | By Darshana | 213
BioAtla Advances Phase 3 Oz-V Programme with Manufacturing-Ready SPV Structure
BioAtla, Inc., a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapies for solid tumours, has entered into a special purpose vehicle (SPV) transaction with GATC Health Corp. to advance its lead asset, ozuriftamab vedotin (Oz-V), into a phase 3 clinical trial for second-line and later OPSCC.
Biotechnology | 04/01/2026 | By Darshana | 181
Mabwell Advances ADC Manufacturing Pipeline With NMPA-Backed Combination Trial Approval
Mabwell, an innovation-driven biopharmaceutical company with fully integrated capabilities spanning research and development, manufacturing, and commercialisation, announced that China’s National Medical Products Administration (NMPA) has approved the initiation of clinical trials for its independently developed B7-H3–targeting antibody–drug conjugate.
Biotechnology | 02/01/2026 | By Darshana | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy